Literature DB >> 8297723

Products of vasopressin gene expression in small-cell carcinoma of the lung.

A S Friedmann1, K A Malott, V A Memoli, S I Pai, X M Yu, W G North.   

Abstract

Small-cell neuroendocrine carcinoma of the lung is known to express products related to the vasopressin gene, although these products have been reported to sometimes differ from those generated by neurones of the hypothalamo-neurohypophyseal system. To further investigate vasopressin gene expression in neuroendocrine carcinomas, we performed immunohistochemistry on 24 histologically classified small-cell carcinomas using antibodies directed against different regions of the vasopressin precursor. All of the tumours examined contained at least two parts of the vasopressin precursor, suggesting that vasopressin might have a biological role in these tumours and indicating a role for these products in tumour diagnosis and treatment. Sixty-seven per cent of the tumours contained immunoreactivity for all major regions of the precursor: vasopressin, vasopressin-associated human neurophysin, the bridging region between the hormone and the neurophysin, and vasopressin-associated human glycopeptide. However, 33% of the tumours examined appeared to express only part of the vasopressin precursor, as evidenced by the absence of immunoreactivity for the neurophysin and/or the glycopeptide. These results support the proposition that both normal and abnormal vasopressin gene expression occurs in small-cell carcinoma of the lung.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8297723      PMCID: PMC1968694          DOI: 10.1038/bjc.1994.49

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Imaging of small cell carcinoma using 131I-labelled antibodies to vasopressin associated human neurophysin (VP-HNP)

Authors:  W G North; V Hirsh; R Lisbona; J Schultz; B Cooper
Journal:  Nucl Med Commun       Date:  1989-09       Impact factor: 1.690

2.  A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone.

Authors:  W B SCHWARTZ; W BENNETT; S CURELOP; F C BARTTER
Journal:  Am J Med       Date:  1957-10       Impact factor: 4.965

3.  The AMeX method. A simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining.

Authors:  Y Sato; K Mukai; S Watanabe; M Goto; Y Shimosato
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

4.  Neurophysins as tumor markers for small cell carcinoma of the lung. A cancer and Leukemia Group B evaluation.

Authors:  W G North; J Ware; L H Maurer; A P Chahinian; M Perry
Journal:  Cancer       Date:  1988-10-01       Impact factor: 6.860

5.  Expression of neurophysin-related precursor in cell membranes of a small-cell lung carcinoma.

Authors:  L C Rosenbaum; E A Neuwelt; H H Van Tol; Y P Loh; J G Verbalis; I Hellström; K E Hellström; G Nilaver
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

6.  Propressophysin in human blood: a possible marker of ectopic vasopressin production.

Authors:  T Yamaji; M Ishibashi; T Hori
Journal:  J Clin Endocrinol Metab       Date:  1984-09       Impact factor: 5.958

Review 7.  Ectopic secretion of neurohypophyseal peptides in patients with malignancy.

Authors:  A M Moses; S J Scheinman
Journal:  Endocrinol Metab Clin North Am       Date:  1991-09       Impact factor: 4.741

8.  Human neurophysins as potential tumor markers for small cell carcinoma of the lung: application of specific radioimmunoassays.

Authors:  W G North; L H Maurer; H Valtin; J F O'Donnell
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

9.  Neuropeptide production by small cell carcinoma: vasopressin and oxytocin as plasma markers of disease.

Authors:  W G North
Journal:  J Clin Endocrinol Metab       Date:  1991-12       Impact factor: 5.958

10.  Isolation and partial characterization of two human neurophysins: their use in the development of specific radioimmunoassays.

Authors:  W G North; F T LaRochelle; J Melton; R C Mills
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

View more
  10 in total

1.  E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small-cell lung cancer.

Authors:  J M Coulson; C E Fiskerstrand; P J Woll; J P Quinn
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

2.  Comparative evaluation of copeptin and NT-proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90-day follow-up period: A prospective clinical observation trial.

Authors:  Jun Jia; Guang-Lei Chang; Shu Qin; Jia Chen; Wen-Yan He; Kai Lu; Yong Li; Dong-Ying Zhang
Journal:  Exp Ther Med       Date:  2017-02-08       Impact factor: 2.447

3.  Vasopressin gene related products are markers of human breast cancer.

Authors:  W G North; S Pai; A Friedmann; X Yu; M Fay; V Memoli
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

4.  Targeting V1A-vasopressin receptors with [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies.

Authors:  Alison C MacKinnon; Uzma Tufail-Hanif; Mark Wheatley; Adriano G Rossi; Christopher Haslett; Michael Seckl; Tariq Sethi
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

5.  Immunohistochemical evaluation of vasopressin expression in breast fibrocystic disease and ductal carcinoma in situ (DCIS).

Authors:  William G North; Wendy Wells; Michael J Fay; Rennie S Mathew; Edward M Donnelly; Vincent A Memoli
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

6.  NMDA receptors are expressed by small-cell lung cancer and are potential targets for effective treatment.

Authors:  William G North; Guohong Gao; Amy Jensen; Vincent A Memoli; Jinlin Du
Journal:  Clin Pharmacol       Date:  2010-04-01

7.  Expression of V1A and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition.

Authors:  A C MacKinnon; U Tufail-Hanif; C D Lucas; D Jodrell; C Haslett; T Sethi
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

8.  Tumour-specific arginine vasopressin promoter activation in small-cell lung cancer.

Authors:  J M Coulson; J Stanley; P J Woll
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

Review 9.  Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy.

Authors:  Mahjabin Khan; Tao Huang; Cheng-Yuan Lin; Jiang Wu; Bao-Min Fan; Zhao-Xiang Bian
Journal:  Oncotarget       Date:  2017-06-07

10.  Growth Impairment of Small-Cell Cancer by Targeting Pro-Vasopressin with MAG-1 Antibody.

Authors:  William G North; Bernard Cole; Bonnie Akerman; Roy H L Pang
Journal:  Front Oncol       Date:  2014-02-11       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.